Psoriasis and Pentoxifylline: A Clinical, Histopathologic, and Immunohistochemical Evaluation

Authors

  • Geraldo Magela Magalhães MD, PhD,

    1. From Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil;1 and Santa Casa de Misericõdia de Belo Horizonte, Minas Gerais, Brazil2
    Search for more papers by this author
  • 1,2 Sueli Coelho Da Silva Carneiro MD, PhD, MSc,

    1. From Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil;1 and Santa Casa de Misericõdia de Belo Horizonte, Minas Gerais, Brazil2
    Search for more papers by this author
  • 1 Karla Peisino Do Amaral MD,

    1. From Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil;1 and Santa Casa de Misericõdia de Belo Horizonte, Minas Gerais, Brazil2
    Search for more papers by this author
  • 1 Flávia De Freire Cássia MD, MSc,

    1. From Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil;1 and Santa Casa de Misericõdia de Belo Horizonte, Minas Gerais, Brazil2
    Search for more papers by this author
  • 1 Jackson Machado-Pinto MD, PhD, MSc,

    1. From Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil;1 and Santa Casa de Misericõdia de Belo Horizonte, Minas Gerais, Brazil2
    Search for more papers by this author
  • and 2 Tullia Cuzzi MD, PhD, MSc 1

    1. From Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil;1 and Santa Casa de Misericõdia de Belo Horizonte, Minas Gerais, Brazil2
    Search for more papers by this author

Geraldo Magela Magalhãs, MD, PhD, Avenida do Contorno, 4747, sala 906. Funcionãrios - Belo Horizonte, Minas Gerais, 30.110-090 Brazil
E-mail: germagela@ig.com.br

Abstract

Objective. The aim of this study was to examine the clinical and histopathologic effects of pentoxifylline on psoriasis, compared with placebo.

Methods. Sixty-one outpatients with active psoriasis were randomly assigned to either of 2 groups: one was given pentoxifylline 400 mg tid PO, and the other, placebo. Fifty-six patients concluded the study. They were evaluated clinically and by laboratory parameters before and after 8 weeks of treatment. Pretreatment and posttreatment biopsies were taken. Initial sections were stained with hematoxylin-eosin. Further cuts were immunostained for cytokeratins 10, 14, and 16.

Results. Clinical and histologic improvement did not show statistically significant differences between the groups. No laboratory abnormalities or serious reactions related to the drug were observed.

Conclusions. No statistical difference was seen when the treatment group was compared with the control group. Pentoxifylline is a well tolerated and safe drug, but its efficacy in psoriasis appears to be limited.

Ancillary